Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bruceine D is a **naturally occurring quassinoid** isolated from *Brucea javanica*, widely studied for its anticancer properties. It is a **tetracyclic triterpene** shown to inhibit proliferation and induce apoptosis in various cancer cell lines, including non-small cell lung cancer, pancreatic cancer, gastric cancer, breast cancer, and leukemia cells. The primary mechanism of action involves **induction of mitochondrial pathway-mediated apoptosis**, characterized by reactive oxygen species (ROS) accumulation, glutathione depletion, disruption of mitochondrial membrane potential, and modulation of apoptosis-related proteins (increased Bax and Bak; decreased Bcl-2, Bcl-xL, and XIAP). Bruceine D can cause cell cycle arrest (at G0-G1 in lung cancer cells and S phase in gastric cancer cells) and may also interfere with signaling pathways involved in cell death and antioxidant defense. It is considered a potential anticancer lead compound and has shown low toxicity in preliminary animal studies[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bruceine d.